InnoCare-Lilly deal could unlock up to $3.35B, with INCPF upside
InnoCare Pharma announced a research collaboration and license agreement with Eli Lilly worth up to about $3.35 billion, signaling validation of InnoCare's platform. The arrangement could unlock milestone- and royalty-driven revenue, serving as a major near-term catalyst for INCPF, though upfront terms and specific milestones are not disclosed.
View signal analysis